The Sanofi and Glaxo SmithKline corporations will seek approval for their coronavirus vaccine candidate, officials announced on Wednesday, stating they hoped their inoculation could be used as either a standalone vaccine or a booster shot with other existing vaccines.
The French-owned Sanofi Pasteur Labs, along with its British partner GlaxoSmithKline are ready to go forward with the cumbersome approval process despite suffering several setbacks on the road to its development.
The companies announced to the press on Wednesday that they intended to submit data to regulators from a late-stage trial of the vaccine as well as another study which looked at its safety and efficacy as a booster only.
Sanofi vaccine paired with adjuvant from Glaxo SmithKline
They added that the full results for both studies should be published sometime “later this year.”